What's happened
South Africa has begun a six-month injectable PrEP rollout using lenacapavir, with officials highlighting equity goals while civil society urges broader access. Reports note clinics have seen benefits and challenges from the new prevention tool and ongoing gaps in specialised services.
What's behind the headline?
Critical analysis
- The rollout marks a calibration between scientific progress and healthcare access. South Africa’s leadership in HIV prevention is underscored by the drug’s efficacy data, yet real-world reach hinges on supply, pricing, and equitable distribution.
- The tension between trials and current access surfaces: trials produced data and local capacity, but ongoing supply and affordability remain uncertain for 3 million targets.
- Expect scrutiny of how quickly generics and local manufacturing can scale. If access remains narrow, the policy risk is undercutting gains with inequity.
- Readers should watch how civil society and donors pressure government and manufacturers to expand doses beyond initial allocations.
How we got here
The rollout follows research showing lenacapavir’s high efficacy in preventing HIV infection and its six-month dosing. Trials in South Africa and Uganda supported its effectiveness, and a Global Fund grant is funding initial doses. The government aims to reach millions with access while addressing distribution and cost concerns, especially for high-risk groups.
Our analysis
All Africa reports on patient experiences and the clinical rollout; AP News covers Ramaphosa’s remarks and the broader context of lenacapavir trials. The Independent adds detail on dosing and national plans. Coverage shows different perspectives on access and equity within SA’s rollout.
Go deeper
- What changes will lenacapavir bring to daily HIV prevention for high-risk groups?
- When will general access expand beyond high-risk populations?
- How will South Africa fund future doses after donor funding ends?
More on these topics
-
Aaron Motsoaledi - Minister of Home Affairs of South Africa
Pakishe Aaron Motsoaledi is the Minister of Home Affairs in the Cabinet of South Africa. He was previously the Minister of Health from 2009 to 2019. He was a MEC in Limpopo province for Education, agriculture and environment, and education.
-
Cyril Ramaphosa - President of South Africa
Matamela Cyril Ramaphosa is a South African politician and the fifth and current President of South Africa. Previously an anti-apartheid activist, trade union leader and businessman, Ramaphosa served as the Deputy President of South Africa from 2014 to 20
-
lenacapavir - Drug
Lenacapavir is an experimental drug for the treatment of HIV being developed by Gilead Sciences. As of 2021, it is in Phase 2/3 clinical trials.
-
South Africa - Country in Southern Africa
South Africa, officially the Republic of South Africa, is the southernmost country in Africa. With over 59 million people, it is the world's 24th-most populous nation and covers an area of 1,221,037 square kilometres.
-
Gilead Sciences - Biotechnology company
Gilead Sciences, Inc., is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs.
-
HIV - Virus
The human immunodeficiency viruses are two species of Lentivirus that infect humans. Over time, they cause acquired immunodeficiency syndrome, a condition in which progressive failure of the immune system allows life-threatening opportunistic infections a
-
United States - Country in North America
The United States of America, commonly known as the United States or America, is a country mostly located in central North America, between Canada and Mexico.